Search results
Results from the WOW.Com Content Network
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. ... Do the numbers hold clues to what lies ahead ...
Five Prime Therapeutics (NASDAQ:FPRX) releases its next round of earnings this Wednesday, March 10. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Investors are focused on the potential extension of the stock market's bull rally heading into 2025. Wall Street experts highlighted the most important stock market charts to watch into next year.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us